Search the Newsreel

Palisade Bio expects once-daily drug trial for bowel disease to start in 2H

Palisade Bio reported Q2 2026 financial results, including a net loss of $10.6 million, and provided an update on its lead Inflammatory Bowel Disease (IBD) candidate, PALI-2108. The company plans to initiate Phase 2 ASCENTRA-UC trials for ulcerative colitis in the second half of …

Palisade Bio Reports Second Quarter 2026 Financial Results

Palisade Bio, Inc. reported its second-quarter 2026 financial results, highlighting the continued advancement of PALI-2108 into Phase 2 development for inflammatory bowel disease (IBD). The company expects to begin enrollment for the Phase 2 ASCENTRA-UC trial in the second half of 2026, with primary …

Renaissance Technologies LLC Lowers Stake in Palisade Bio, Inc. $PALI

Renaissance Technologies LLC decreased its stake in Palisade Bio, Inc. by 39% in the first quarter, selling 928,100 shares but still owning 1.45 million shares valued at approximately $2.55 million. Despite this, institutional investors collectively hold 11.79% of PALI, and analysts maintain a consensus …

Price to sales forward of Calisa Acquisition Corp – NASDAQ:ALISR

The article provides a brief financial overview of Calisa Acquisition Corp (NASDAQ: ALISR), specifically highlighting its "Price to sales forward" metric. It appears to be a stub or a data point from TradingView, indicating that the market was closed and no trades had occurred …

Tempus AI Stock Drops As $1.5B Personalis Deal Ups The MRD Stakes

Tempus AI is acquiring Personalis in an all-stock deal valued at $1.5 billion, which positions Tempus AI strategically in the high-growth MRD oncology market. Despite the long-term strategic benefits, Tempus AI's stock experienced a dip following the announcement due to market concerns over valuation, …

Wedbush Adjusts Price Target on Zentalis Pharmaceuticals to $5 From $4, Maintains Neutral Rating

Wedbush has adjusted its price target for Zentalis Pharmaceuticals (ZNTL) to $5, an increase from the previous $4. The firm has decided to maintain its Neutral rating on the company's stock. This change reflects Wedbush's updated valuation for Zentalis Pharmaceuticals.

Calisa Acquisition Corp 2Q 2026: Net income $372357 EPS $0.04— 10-Q Summary

Calisa Acquisition Corp reported a net income of $372,357 for the second quarter of 2026, marking a significant improvement from a net loss in the prior year, with diluted earnings per share at $0.04. The company's primary activities involved target identification and due diligence …

Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Hold" from Analysts

Personalis, Inc. (NASDAQ:PSNL) has received an average "Hold" rating from nine analysts, with a 12-month average price target of $14.25. Recent insider selling by executives, totaling over $5.6 million in shares, has been noted. The company's latest quarterly earnings showed mixed results, with revenue …

Zentalis Highlights Q2 Results and Azenosertib Progress

Zentalis Pharmaceuticals reported its Q2 2026 results and provided an update on the progress of azenosertib, its drug for Cyclin E1-positive platinum-resistant ovarian cancer. The company maintains a cash runway into late 2027 and is advancing its DENALI trial, aiming for an integrated topline …

American Exceptionalism Acquisition Ord Shs Class A

AtkinsRéalis Group (TSX:ATRL) Could Be 25% Undervalued As Earnings Land

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. AtkinsRéalis Group (TSX:ATRL) is back in focus after its second quarter 2026 update, which combined fresh earnings, an unchanged dividend, active share buybacks, and plans …

AtkinsRéalis Group (TSX:ATRL) Stock Looks Cheap But Earnings Quality Clouds Upside

Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $7.44, Implies 49% Upside

Analysts have raised the average 12-month price target for Zentalis Pharmaceuticals, Inc. (ZNTL) stock to $7.44, up from $7.22, with individual forecasts ranging from $4 to $11 per share. This updated target suggests a potential upside of approximately 49% from the August 6th closing …

Goodvision AI deal gives Calisa Acquisition (NASDAQ: ALIS) path to merger

Calisa Acquisition Corp (ALIS) reported its Q2 2026 earnings and details of its proposed business combination with Goodvision AI Inc. The merger terms include 18,000,000 shares for Goodvision AI, plus potential earnout shares based on performance targets, and secured equity subscriptions for additional Class …

AtkinsRéalis Group (TSX:ATRL) Is Up 5.9% After Nuclear Backlog Surge And Aggressive Buybacks - Has The Bull Case Changed?

In the second quarter of 2026, AtkinsRéalis Group reported higher sales of CA$2,985.27 million, sharply lower net income of CA$95.73 million, continued a CA$0.02 per share dividend, completed a CA$241.7 million buyback of 2,772,713 shares, and signalled plans for further acquisitions, including a potential …

Personalis (PSNL) Is Up 6.1% After Q2 Revenue Rises But Losses Deepen - What's Changed

Personalis, Inc. (PSNL) saw its stock rise by 6.1% after reporting a 30% increase in Q2 revenue to US$22.36 million year-over-year, although net losses deepened to US$31.68 million. Despite flat sales for the first half of 2026, the company reaffirmed its full-year revenue guidance …

Cancer Detection Test Receives Regulatory Marking for Use in Great Britain

Personalis Inc. has received UKCA marking for its NeXT Personal Dx test, allowing its clinical use for minimal residual disease detection in Great Britain. This regulatory approval enables pharmaceutical companies to use the platform in multi-national clinical trials, standardizing detection and potentially accelerating drug …

Personalis Inc (PSNL) Stock News Today

Zentalis Pharmaceuticals, Inc. 2Q 2026: Net loss $(42.3M), EPS $(0.59) — 10-Q Summary

Zentalis Pharmaceuticals, Inc. reported a net loss of $(42.3M) and a diluted loss per share of $(0.59) for the second quarter of 2026, remaining a pre-revenue company. The company is advancing its clinical development for azenosertib, including a Phase 3 study and biomarker strategy, …

Growth Potential For Personalis, Inc. (PSNL): A Look At Its 30% Revenue Surge

Personalis, Inc. (PSNL) shows promising growth in the Diagnostics & Research industry, highlighted by a 30% revenue surge driven by its advanced cancer genomic tests. Despite financial challenges like negative EPS and free cash flow deficits, analyst sentiment remains cautiously optimistic, with potential upside …

Palisade Bio CEO, CFO Finley sells $303k in stock

John David Finley, CEO and CFO of Palisade Bio (NASDAQ:PALI), sold 146,798 shares for approximately $303,343 to cover tax obligations following the vesting of restricted stock units. This transaction occurred after a significant 184% return over the past year, though InvestingPro data suggests the …

Chemfab Alkalis Consolidated June 2026 Net Sales at Rs 73.16 crore, down 20.08% Y-o-Y

Renaissance Technologies LLC Lowers Position in Zentalis Pharmaceuticals, Inc. $ZNTL

Morgan Stanley Adjusts PT on Zentalis Pharmaceuticals to $5 From $4, Maintains Equalweight Rating

Morgan Stanley has increased its price target for Zentalis Pharmaceuticals (ZNTL) from $4 to $5, while reiterating an "Equalweight" rating on the stock. This adjustment reflects a modest upgrade in the firm's outlook for the clinical-stage biopharmaceutical company, which specializes in developing small molecule …

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals announced its Q2 2026 financial results, reporting $174.6 million in cash, providing runway into late 2027. The company highlighted progress in its late-stage WEE1 inhibitor, azenosertib, for ovarian cancer, with the DENALI trial's accelerated approval strategy intact following FDA discussions. Topline data …

Medalist Diversified REIT Finalizes Major Asset Disposition

AtkinsRéalis Reports Second Quarter 2026 Results

Revenue of $3.0 billion, up 10%, and Segment Adjusted EBIT up 10%, over Q2 2025 Adjusted EBITDA(1) up 14%, over Q2 2025, to a quarterly record high Diluted EPS of $0.59 and Adjusted diluted EPS(1)(5) of $0.97, up 20% over Q2 2025 Net cash …

Personalis Inc (PSNL) News, Articles, Events & Latest Updates

This article compiles recent news and updates for Personalis Inc (PSNL), primarily focusing on its Q2 2026 financial results, which reported a loss but topped revenue estimates, and the significant acquisition by Tempus AI for $1.5 billion. Several reports also highlight ongoing legal inquiries …

Palisade Bio Inc (PALI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Palisade Bio Inc (PALI), highlighting its current earnings forecast score of 8.80 and an average price target of $8.00 based on 10 analyst ratings. Most analysts recommend a "Buy" for PALI, with expected EPS for the next …

Personalis (PSNL) Stock Commands A Premium Despite Deepening Losses

Personalis (PSNL) stock maintains a premium valuation despite reporting deepening losses in Q2 2026, with revenue at US$22.36 million and a net loss of US$31.68 million. While the company has achieved milestones like Medicare coverage for its MRD platform and regulatory wins in the …

BlackRock, Inc. Expands Stake in Zentalis Pharmaceuticals (ZNTL) with Strategic Share Addition

BlackRock, Inc. has increased its stake in Zentalis Pharmaceuticals (ZNTL) by purchasing 2,441,077 additional shares, bringing its total ownership to 5.20% of the company's outstanding shares. This strategic move, executed at $4.85 per share, reflects BlackRock's confidence in the clinical-stage biopharmaceutical company's long-term prospects, …

Materialise (NASDAQ:MTLS) Stock Passes Above 50-Day Moving Average - What's Next?

Materialise (NASDAQ:MTLS) shares recently surpassed their 50-day moving average, trading at $6.70 against an average of $6.71, with a high of $6.74. Despite this, analyst sentiment remains cautious, with a consensus "Hold" rating and a $10.00 price target, following a downgrade from "strong buy" …

Personalis (NASDAQ: PSNL) posts larger loss and strikes Tempus cash-stock merger

Personalis, a cancer genomics testing company, reported a wider loss in Q2 2026 despite increased revenue, driven by higher operating expenses. The company announced it has entered into a merger agreement to be acquired by Tempus AI, Inc. in a cash-stock deal. The merger …

Personalis Reports Second Quarter 2026 Results and Recent Highlights

Personalis, Inc. reported strong financial results for the second quarter of 2026, with revenue growing 30% year-over-year to $22.4 million and clinical test volume surging 199%. Key achievements include securing Medicare coverage for its NeXT Personal® test for immunotherapy monitoring and neoadjuvant breast cancer …

Personalis (NASDAQ:PSNL) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS